Background
==========

As a chronic inflammatory respiratory disease, asthma is characterized by episodic bronchoconstriction and airway hyper-responsiveness to a variety of stimuli, such as viral antigens, allergens, and environmental exposures, and may cause shortness of breath, chest tightness, coughing, and wheezing \[[@b1-medscimonit-22-2800]\]. It has been reported that 25.9 million (8.5%) people in the United States had asthma in 2011, including 7.0 million children, with increasing prevalence rates \[[@b2-medscimonit-22-2800]\]. Chronic obstructive pulmonary disease (COPD) is mainly characterized by progressive and irreversible development of persistent airway obstruction \[[@b3-medscimonit-22-2800],[@b4-medscimonit-22-2800]\]. Acute exacerbations of COPD (AECOPD) are episodes of sustained worsening of symptoms and decline of lung function, which reflects an extensive inflammatory process at onset stage; it contributes to poor life quality and is a major cause of mortality and morbidity \[[@b5-medscimonit-22-2800],[@b6-medscimonit-22-2800]\]. Asthma and COPD may coexist, or one condition may evolve into the other, creating a condition commonly known as Asthma and COPD Overlap Syndrome (ACOS), which has indistinct clinical and pathophysiological features of asthma or COPD \[[@b7-medscimonit-22-2800],[@b8-medscimonit-22-2800]\]. Compared to other individuals with COPD, patients with ACOS have an increased reversibility of airflow obstruction and, more importantly, a higher degree of eosinophilic bronchial inflammation \[[@b9-medscimonit-22-2800]\]. Since all these 3 diseases are related to inflammatory processes, it is of great importance to study the roles of inflammatory cytokine levels in the development of these diseases.

Interleukin (IL)-4, also known as B-cell-stimulating factor, is a pleiotropic cytokine. It mainly promotes the proliferation of T cells and induces antibody production by B cells, and can also stimulate proliferation, differentiation, and activation of fibroblasts, and endothelial and epithelial cells, and increases the recruitment of inflammatory cells \[[@b10-medscimonit-22-2800],[@b11-medscimonit-22-2800]\]. As an essential pro-inflammatory mediator, IL-8 can be produced by monocytes/macrophages, epithelial cells, smooth muscle cells, and endothelial cells. It is involved in cancer development and acts as an angiogenic growth factor in the progression and metastasis of non-small cell lung cancer \[[@b12-medscimonit-22-2800],[@b13-medscimonit-22-2800]\]. IL-10 is a major anti-inflammatory cytokine and is a necessary and beneficial host response directed at regulating excessive pro-inflammatory cytokines and chemokines from respiratory syncytial virus-activated immune cells \[[@b14-medscimonit-22-2800]\]. It has been reported that IL-10 can suppress macrophage activity by inhibiting the production of interferon gamma, IL-2, IL-12, and IL-18 and that the modulation of the inflammatory response is essential to preserve immune system balance \[[@b15-medscimonit-22-2800]\]. Tumor necrosis factor α (TNF-α) is a multifunctional and pro-inflammatory cytokine that can respond to inflammation, infection, and injury by mast cells, macrophages, eosinophils, epithelial cells, and neutrophils in asthma pathogenesis \[[@b16-medscimonit-22-2800]\]. However, few studies have systematically investigated the inflammatory cytokine levels in patients with asthma, AECOPD, and ACOS.

Therefore, in this study, we detected and compared the plasma IL-4, IL-8, and IL-10, and TNF-α levels in patients with asthma, AECOPD, and ACOS and conducted correlation studies to analyze the correlations between the inflammatory cytokine levels and pulmonary function.

Material and Methods
====================

Study participants
------------------

Between January 2013 and December 2014, a total of 96 patients with asthma, AECOPD, or ACOS were enrolled from the Department of Respiratory Medicine, South Campus, Shanghai Jiaotong University 6th Hospital. Using the "Bronchial Asthma Therapeutic Guidelines" formulated by the Branch of Chinese Medical Association for Respiratory Diseases \[[@b17-medscimonit-22-2800]\], 36 patients with acute exacerbation of bronchial asthma were enrolled as the asthma group. According to the "Chronic Obstructive Pulmonary Disease Therapeutic Guidelines" (Branch of Chinese Medical Association for Respiratory Diseases) \[[@b18-medscimonit-22-2800]\], 32 patients with AECOPD were enrolled as the AECOPD group. Based on the "Diagnostic Criteria Consensus of Chronic Obstructive Pulmonary Disease-Asthma Overlap Syndrome" published in 2012 \[[@b19-medscimonit-22-2800]\], 28 patients with acute exacerbation of ACOS were recruited as the ACOS group. Exclusion criteria were: patients with other lung diseases (e.g., bronchiectasis, lung cancer, pulmonary embolism, interstitial lung disease, and tuberculosis), severe heart, liver, kidney, or systemic diseases; and worm parasites in stool samples. We enrolled 35 healthy subjects as the control group. The study complied with the medical ethics standards and was approved by the Ethics Committee of Shanghai Jiaotong University 6^th^ Hospital. Signed informed consent was obtained from all study subjects or their families. Ethics approval for this study conformed to the standards of the Declaration of Helsinki \[[@b20-medscimonit-22-2800]\].

Indicator assessment
--------------------

Venous blood (5 ml) was taken from each participant. Whole blood was collected using ethylene diamine tetraacetic acid (EDTA) tubes and naturally coagulated for about 20 minutes at room temperature, and centrifuged at 2000 r/min for 10 minutes. The supernatant was collected carefully and stored at −70°C. Enzyme-linked immunosorbent assay (ELISA) was used to detect plasma IL-4, IL-6, IL-8, IL-10, and TNF-α levels; all the kits were provided by Shenzhen Jingmei Co., Ltd., Shenzhen, China, and all the plasma sample processing, measurement, and content calculation were done according to kit instructions.

A Microtest 1 analyzer (Alifax Company, Italy) was used to detected erythrocyte sedimentation rate (ESR). A Sysmex XE-2100D automated hematology analyzer (Sysmex, Japan) was used to detect peripheral blood eosinophil count. Plasma α1-antitrypsin was detected by a Roche automated clinical chemistry analyzer (Roche, Germany) and determined by immune nephelometry method; reagents were provided by the Roche Company and the procedures done were in accordance with kit instructions. Serum total protein immunoglobulin E (IgE) was measured by use of a BN-II special protein analyzer (Siemens, Germany) and determined by immune nephelometry method; the reagents were supplied by the Siemens Company and the procedures were done in accordance with kit instructions. A MedGraphics 1085 Series Plethysmography (MedGraphics CPX/D, St Paul, MN, USA) was used to conduct pulmonary function testing and bronchial dilation testing. We measured arterial partial pressure of oxygen (PaO~2~), arterial partial pressure of carbon dioxide (PaCO~2~) in blood, forced expiratory volume in 1 second percentage (FEV1%), forced vital capacity (FVC), FEV1/FVC, FEV1/predicted value ratio (FEV1%pred), total lung capacity (TLC), and residual volume (RV) of subjects in each group.

Statistical methods
-------------------

SPSS 21.0 statistical software (SPSS Inc, Chicago, IL, USA) was used for statistical data processing. Count data are expressed as percentages or rates, and were compared using the chi-square test between groups; measurement data are presented as mean±standard deviation and were compared using the *t* test between 2 groups, and analysis of variance (ANOVA) was used among groups. Pearson correlation analysis was used for correlation analysis. All tests were 2-sided and *P*\<0.05 indicated a significant difference.

Results
=======

Clinical and laboratory characteristics
---------------------------------------

As shown in [Table 1](#t1-medscimonit-22-2800){ref-type="table"}, no significant differences in age, sex, body mass index (BMI), smoking status, smoking index, or allergic history were found among the control group, the asthma group, AECOPD group, and ACOS group (all *P*\>0.05); but obvious differences in α1-antitrypsin level, serum total IgE, ESR, and peripheral blood eosinophil were found among the 4 groups (all *P*\<0.05). The α1-antitrypsin level in the control group was remarkably lower than in the 3 patient groups (all *P*\<0.05); serum total IgE was significantly higher in the asthma and ACOS groups than that in the control group (both *P*\<0.05). ESR was obviously different between the AECOPD group and the control group (*P*\<0.05). Statistically significant differences in peripheral blood eosinophil counts were found between the control group and the asthma group, and between the control group and the ACOS group (both *P*\<0.05).

No significant differences in age, BMI, smoking index, allergic history, α1-antitrypsin level, serum total IgE, ESR, or peripheral blood eosinophil were found among the asthma group, AECOPD group, and ACOS group (all *P*\>0.05). A significant difference in sex was found among the 3 groups of patients (*P*=0.029). The line × column table was further divided based on sex, the test standard and free degree were corrected, and the threshold χ^2^~0.0167,1~ was 5.73. Comparing the asthma group and the ACOS group, the χ^2^=3.78 \<χ^2^~0.0167,1~, comparing the AECOPD group and ACOS group, the χ^2^=0.19 \<χ^2^~0.0167,1~; and comparing the asthma group and AECOPD group, the χ^2^=6.35 \>χ^2^~0.0167,1~, which indicated that the proportion of males in the AECOPD group was higher than that in the asthma group (*P*\<0.05), but was not significantly different compared to the ACOS group (*P*\>0.05). Differences in smoking status was found among the 3 groups of patients (*P*=0.019). The table was further divided based on smoking status, and test standard and free degree were corrected, the threshold χ^2^~0.0167,1~ was 5.73, the χ^2^ was 9.84 comparing the asthma and ACOS group and was more than the threshold value; it was 8.88 comparing the asthma group and AECOPD group and was also more than the threshold value, and was 0.06 comparing the AECOPD group and ACOS group and was less than the threshold value, indicating the percentage of patients with smoking history was higher in the AECOPD group than that in the asthma group, but it was not significantly different compared to the ACOS group.

Comparisons of pulmonary function indexes
-----------------------------------------

The PaO~2~, FEV1, and FEV1%pred were higher, while the FVC, RV, and RV/TLC were lower, in the control group than in the asthma group, AECOPD group, and ACOS group (all *P*\<0.05). No significant differences in PaCO~2~ and TLC were found among the 4 groups (both *P*\>0.05).

PaO~2~ was lower in the AECOPD group than in the asthma group, with a statistically significant difference (*P*\<0.01); while there were no significant difference in PaO~2~ between the asthma group and the ACOS group, and the AECOPD group and ACOS group (both *P*\>0.05). PaCO~2~, FEV1, FEV1~improved~, TLC, FVC, and RV (after inhalation of bronchodilators) were not significantly different among the 3 groups of patients (all *P*\>0.05). The FEV1%pred was remarkably different between the asthma group and ACOS group (*P*\<0.05); but was not significantly different between the asthma group and AECOPD group, and the AECOPD group and ACOS group (both *P*\>0.05). The FEV1/FVC and the RV/TLC were significantly different among the 3 groups of patients (*P*\<0.01; *P*=0.003) ([Table 2](#t2-medscimonit-22-2800){ref-type="table"}).

Comparisons of plasma inflammatory cytokine levels
--------------------------------------------------

The IL-4, IL-8, IL-10, and TNF-α levels were significantly different among the control group, asthma group, AECOPD group, and ACOS group (all *P*\<0.05) ([Table 3](#t3-medscimonit-22-2800){ref-type="table"}). IL-4 and IL-8 levels showed statistically significant differences among the 3 groups of patients (F=14.78, *P*\<0.001; F=20.43, *P*\<0.001). The IL-4 level was significantly lower but the IL-8 level was significantly higher in the AECOPD group and ACOS group than those in the asthma group (all *P*\<0.05). The IL-4 and IL-8 levels were not significantly different between the AECOPD group and ACOS group. IL-10 level and TNF-α level were significantly different among the 3 patient groups (both *P*\<0.001). IL-10 level was significantly different between each of the 2 groups (all *P*\<0.001). TNF-α level in the asthma group was higher than in the AECOPD group and ACOS group (*P*\<0.001), but was not significantly different between the AECOPD group and the ACOS group ([Figure 1](#f1-medscimonit-22-2800){ref-type="fig"}).

Correlations between plasma inflammatory cytokine levels and pulmonary function indexes
---------------------------------------------------------------------------------------

As shown in [Table 4](#t4-medscimonit-22-2800){ref-type="table"}, the plasma level of IL-4 was positively correlated with FEV1, FEV1%pred, and FEV1/FVC (r=0.297, 0.240 and 0.390; all *P*\<0.05) ([Figure 2](#f2-medscimonit-22-2800){ref-type="fig"}); the plasma level of IL-8 was negatively correlated with FEV1, FEV1%pred, and FEV1/FVC (r=−0.580, −0.641 and r=−0.455, all *P*\<0.05) ([Figure 3](#f3-medscimonit-22-2800){ref-type="fig"}); the IL-10 plasma level was positively correlated with FEV1, FEV1%pred, and FEV1/FVC (r=0.535, 0.580 and 0.477; all *P*\<0.05) ([Figure 4](#f4-medscimonit-22-2800){ref-type="fig"}); and the TNF-α plasma level was negatively correlated FEV1, FEV1%pred, and FEV1/FVC (r=−0.494, −0.491 and −0.452, all *P*\<0.05) ([Figure 5](#f5-medscimonit-22-2800){ref-type="fig"}).

Discussion
==========

Our study demonstrated that in the control group, PaO~2~, FEV1, and FEV1%pred were higher and the FVC, RV, and RV/TLC were lower than that in the asthma group, AECOPD group, and ACOS group. Our results suggest that PaO~2~ was significantly lower in the AECOPD group than in the asthma group; therefore, PaO~2~ could be a valuable index to differentiate AECOPD and asthma. As a sensitive and objective measure of pulmonary function, PaO~2~ is a very good predictor of the severity of lung lesions induced by virulent bovine respiratory syncytial virus \[[@b21-medscimonit-22-2800]\]. PaO~2~ less than 8.0 kPa (60 mmHg) is used to define hypoxemic respiratory failure; chronic hypoxemia is a serious complication of COPD and is related to increased mortality \[[@b22-medscimonit-22-2800]\].

The FEV1%pred was remarkably different between the asthma group and the ACOS group; FEV1 measurement plays key roles in establishing the diagnosis of COPD, and decreasing FEV1 is correlated with increased respiratory mortality \[[@b23-medscimonit-22-2800]\]. In addition, FEV1 was used to monitor a progressive decline in pulmonary function in patients with cystic fibrosis and greater rates of FEV1 decline was associated with poorer survival and the need for earlier lung transplantation \[[@b24-medscimonit-22-2800]\]. Decreased FEV1%pred was associated with greater airway wall area and thickness and smaller airway luminal area, while higher FEV1%pred implies better airway condition and better ventilatory function \[[@b25-medscimonit-22-2800]\]. FEV1%pred was significantly lower in the ACOS group than in the asthma group, further confirming that ACOS might be severe in disease condition and narrow in airway. Pathologically, structural changes in the small airways contribute to asthma-like features in ACOS and COPD patients, with a thicker reticular basement membrane than in COPD patients without these features \[[@b26-medscimonit-22-2800]\].

FEV1/FVC and RV/TLC were significantly different among the 3 groups of patients. FVC has been a standard spirometric measure of pulmonary function in idiopathic pulmonary fibrosis. Longitudinal change in FVC is a widely accepted indication of disease progression \[[@b27-medscimonit-22-2800]\]. The difference between vital capacity (VC) and FVC can be used as an index to measure the severity of airflow limitation and as a predictor in exercise performance of COPD patients \[[@b28-medscimonit-22-2800]\]. Moreover, it has been demonstrated that RV/TLC is an independent risk factor for all-cause mortality in COPD \[[@b26-medscimonit-22-2800]\]. As a parameter used to define the presence of airflow limitation, FEV1/FVC ratio has been recommended as an index to diagnose patients with COPD and those at risk, and a low FEV1/FVC ratio after bronchodilator use might indicate the need for corticosteroid therapy in mild asthma \[[@b29-medscimonit-22-2800]--[@b31-medscimonit-22-2800]\]. The differences in pulmonary function index in patients with asthma, AECOPD, and ACOS could help to diagnose these 3 diseases more quickly and accurately, which is of great clinical importance \[[@b32-medscimonit-22-2800]\].

For plasma inflammatory cytokines, the result showed that the IL-4, IL-8, IL-10, and TNF-α levels were significantly different among the control group, asthma group, AECOPD, group and ACOS group. IL-4 level was significantly lower while IL-8 level was significantly higher in the AECOPD group and ACOS group than in the asthma group. As a pleiotropic cytokine, IL-4 plays a crucial role in type 2 T-helper responses and isotype class switching of B cells to IgE synthesis, and it has thus been suggested that IL-4 may have an important role in asthma pathogenesis \[[@b34-medscimonit-22-2800],[@b34-medscimonit-22-2800]\]. IL-8 has chemotaxis of target cells to the site of inflammation during the inflammatory process and was observed to be released in greater quantities in patients who continue their smoking habit, and was more elevated in individuals with COPD than in smokers without flow obstruction \[[@b12-medscimonit-22-2800],[@b31-medscimonit-22-2800]\]. The different expressions of IL-4 and IL-8 might be useful in differentiating AECOPD and ACOS from asthma. Systemic inflammation is commonly present in ACOS, and ACOS resembles COPD in terms of systemic inflammation \[[@b35-medscimonit-22-2800]\].

IL-10 level was significantly different between each of the 2 groups. TNF-α level in the asthma group was higher than in the AECOPD group and the ACOS group. IL-10 has been shown to suppress all the pro-inflammatory cytokines, IL-10 activity is mediated by specific cell surface receptor complex, and lower IL-10 levels were reported to be associated with a higher frequency of bronchial asthma and COPD \[[@b14-medscimonit-22-2800],[@b36-medscimonit-22-2800]\]. Persistently increased production of TNF-α in response to lipopolysaccharide-stimulated blood mononuclear cells at birth and at 3 months is a predictor for the development of childhood asthma \[[@b37-medscimonit-22-2800]\].

Correlation studies showed that IL-4 and IL-10 were positively related, while IL-8 and TNF-α were negatively related with FEV1, FEV1%pred, and FEV1/FVC, which indicates that the roles of plasma inflammatory cytokine levels in the patients with asthma, AECOPD, and ACOS might be associated with their effects on pulmonary function indexes. However, the detailed mechanisms involved in determining plasma inflammatory cytokine levels and the pulmonary function indexes need further study.

Conclusions
===========

Our study shows that plasma levels of inflammatory cytokines IL-4, IL-8, IL-10, and TNF-α were significantly different among control, asthma, AECOPD, and ACOS groups and might be useful indexes for use in assessing the development of these diseases. The inflammatory cytokines might be related with pulmonary function indexes, which might explain how inflammatory cytokines affect asthma, AECOPD, and ACOS, but the detailed mechanism still needs further investigation.
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###### 

Clinical and laboratory characteristics in control, asthma, AECOPD and ACOS groups.

                                          Control group   Asthma group                                                       AECOPD group                                                    ACOS group                                                        *P*
  --------------------------------------- --------------- ------------------------------------------------------------------ --------------------------------------------------------------- ----------------------------------------------------------------- ---------
  Age                                     55.7±10.3       56.1±14.3                                                          60.2±10.1                                                       53.4±10.7                                                         0.146
  Gender                                                                                                                                                                                                                                                       
   Male                                   19 (54.28)      14 (38.89)                                                         21 (65.62)                                                      19 (67.86)                                                        0.052
   Female                                 16 (45.72)      22 (61.11)                                                         11 (34.38)                                                      9 (32.14)                                                         
  BMI (kg/m^2^)                           25.98±5.31      25.01±5.64                                                         26.02±3.21                                                      27.68±4.02                                                        0.171
  Smoking status                                                                                                                                                                                                                                               
   Never smoking                          16 (45.71)      20 (55.56)                                                         11 (34.38)                                                      9 (32.14)                                                         0.062
   Used to smoke                          12 (34.28)      5 (13.89)                                                          15 (46.87)                                                      14 (50.00)                                                        
   Still smoking                          7 (20.01)       11 (30.55)                                                         6 (18.75)                                                       5 (17.86)                                                         
  Smoking index                                                                                                                                                                                                                                                
   0                                      16 (45.71)      20 (55.56)                                                         11 (34.38)                                                      10 (35.72)                                                        0.306
   0--200                                 7 (20.01)       5 (13.89)                                                          3 (9.37)                                                        4 (14.28)                                                         
   \>200                                  12 (34.28)      11 (30.55)                                                         18 (56.25)                                                      14 (50.00)                                                        
  Allergic history                                                                                                                                                                                                                                             
   No                                     25 (71.43)      18 (50.00)                                                         23 (71.88)                                                      15 (53.57)                                                        0.128
   Yes                                    10 (28.57)      18 (50.00)                                                         9 (28.12)                                                       13 (46.43)                                                        
  α1-antitrypsin (mg/dL)                  128.8±6.1       143.9±3.5[\*](#tfn2-medscimonit-22-2800){ref-type="table-fn"}      147.2±8.4[\*](#tfn2-medscimonit-22-2800){ref-type="table-fn"}   145.9±5.1[\*](#tfn2-medscimonit-22-2800){ref-type="table-fn"}     \<0.001
  Serum total IgE (IU/ml)                 103.0±49.6      382.8 ±412.0[\*](#tfn2-medscimonit-22-2800){ref-type="table-fn"}   189.0±191.2                                                     306.4±336.7[\*](#tfn2-medscimonit-22-2800){ref-type="table-fn"}   0.001
  ESR (mm/h)                              12.5±3.1        16.4±10.1                                                          18.9±11.9[\*](#tfn2-medscimonit-22-2800){ref-type="table-fn"}   13.1±6.2                                                          0.010
  Peripheral blood eosinophil (10^9^/L)   0.14±0.07       0.29±0.17[\*](#tfn2-medscimonit-22-2800){ref-type="table-fn"}      0.22±0.12                                                       0.28±0.22[\*](#tfn2-medscimonit-22-2800){ref-type="table-fn"}     0.001

*P* -- comparisons between control, asthma, AECOPD and ACOS.

Compared with the control group, *P*\<0.05.

AECOPD -- acute exacerbation of chronic obstructive pulmonary disease; ACOS -- asthma-chronic obstructive pulmonary disease overlap syndrome; BMI -- body mass index; IgE -- immunoglobulin E; ESR -- erythrocyte sedimentation rate.

###### 

Comparisons of pulmonary function indexes among control, asthma, AECOPD and ACOS groups.

                     Control group   Asthma group                                                    AECOPD group                                                                                                         ACOS group                                                                                                           *P*
  ------------------ --------------- --------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------- ---------
  PaO~2~ (mmHg)      84.1±8.4        79.1±10.6                                                       69.9±12.0[\*](#tfn5-medscimonit-22-2800){ref-type="table-fn"},[\#](#tfn6-medscimonit-22-2800){ref-type="table-fn"}   76.2±12.8[\*](#tfn5-medscimonit-22-2800){ref-type="table-fn"}                                                        \<0.001
  PaCO~2~ (mmHg)     42.1±7.8        38.8±10.4                                                       44.9±10.1                                                                                                            41.6±12.1                                                                                                            0.107
  FEV1 (L)           2.75±0.09       1.86±0.92[\*](#tfn5-medscimonit-22-2800){ref-type="table-fn"}   1.60±0.64[\*](#tfn5-medscimonit-22-2800){ref-type="table-fn"}                                                        2.08±0.80[\*](#tfn5-medscimonit-22-2800){ref-type="table-fn"}                                                        \<0.001
  FEV1improved (L)                   0.35±0.16                                                       0.52±0.47                                                                                                            0.42±0.16                                                                                                            
  FEV1%pred (%)      85.1±2.6        70.3±20.8[\*](#tfn5-medscimonit-22-2800){ref-type="table-fn"}   65.1±12.6[\*](#tfn5-medscimonit-22-2800){ref-type="table-fn"}                                                        54.3±22.9[\*](#tfn5-medscimonit-22-2800){ref-type="table-fn"},[\#](#tfn6-medscimonit-22-2800){ref-type="table-fn"}   \<0.001
  FVC (L)            2.87±0.94       3.58±0.98[\*](#tfn5-medscimonit-22-2800){ref-type="table-fn"}   3.50±0.74[\*](#tfn5-medscimonit-22-2800){ref-type="table-fn"}                                                        4.07±1.18[\*](#tfn5-medscimonit-22-2800){ref-type="table-fn"}                                                        \<0.001
  FEV1/FVC (%)       76.2±1.1        51.0±2.8[\*](#tfn5-medscimonit-22-2800){ref-type="table-fn"}    46.2±1.3[\*](#tfn5-medscimonit-22-2800){ref-type="table-fn"},[\#](#tfn6-medscimonit-22-2800){ref-type="table-fn"}    48.6±1.8[\*](#tfn5-medscimonit-22-2800){ref-type="table-fn"},[\#](#tfn6-medscimonit-22-2800){ref-type="table-fn"}    \<0.001
  TLC (L)            4.85±1.05       4.64±1.60                                                       5.41±1.22                                                                                                            4.82±1.45                                                                                                            0.115
  RV (L)             1.28±0.22       1.68±0.92                                                       2.15±0.84[\*](#tfn5-medscimonit-22-2800){ref-type="table-fn"}                                                        1.84±0.56[\*](#tfn5-medscimonit-22-2800){ref-type="table-fn"}                                                        \<0.001
  RV/TLC             30.1±8.6        47.6±9.9[\*](#tfn5-medscimonit-22-2800){ref-type="table-fn"}    56.4±10.5[\*](#tfn5-medscimonit-22-2800){ref-type="table-fn"},[\#](#tfn6-medscimonit-22-2800){ref-type="table-fn"}   50.8±11.2[\*](#tfn5-medscimonit-22-2800){ref-type="table-fn"},[\#](#tfn6-medscimonit-22-2800){ref-type="table-fn"}   \<0.001

*P* -- comparisons between control, asthma, AECOPD and ACOS.

Compared with the control group, *P*\<0.05;

Compared with the asthma group, *P*\<0.05.

AECOPD -- acute exacerbation of chronic obstructive pulmonary disease; ACOS -- asthma-chronic obstructive pulmonary disease overlap syndrome; PaO~2~ -- arterial partial pressure of oxygen; PaCO~2~ -- arterial partial pressure of carbon dioxide; FEV1 -- forced expiratory volume in 1 second, FEV1%pred -- FEV1/predicted value ratio; FVC -- forced vital capacity; TLC -- total lung capacity; RV -- residual volume.

###### 

Comparisons of plasma inflammatory cytokine levels among control, asthma, AECOPD and ACOS groups.

                 Control group   Asthma group                                                       AECOPD group                                                                                                             ACOS group                                                                                                                                                                  *P*
  -------------- --------------- ------------------------------------------------------------------ ------------------------------------------------------------------------------------------------------------------------ --------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------
  IL-4 (ng/L)    55.08±9.86      205.12±72.58[\*](#tfn9-medscimonit-22-2800){ref-type="table-fn"}   140.50±20.66[\*](#tfn9-medscimonit-22-2800){ref-type="table-fn"},[\#](#tfn10-medscimonit-22-2800){ref-type="table-fn"}   167.31±32.42[\*](#tfn9-medscimonit-22-2800){ref-type="table-fn"},[\#](#tfn10-medscimonit-22-2800){ref-type="table-fn"}                                                      \<0.001
  IL-8 (ng/L)    29.10±5.02      46.59±4.72[\*](#tfn9-medscimonit-22-2800){ref-type="table-fn"}     52.68±5.64[\*](#tfn9-medscimonit-22-2800){ref-type="table-fn"},[\#](#tfn10-medscimonit-22-2800){ref-type="table-fn"}     56.25±6.61[\*](#tfn9-medscimonit-22-2800){ref-type="table-fn"},[\#](#tfn10-medscimonit-22-2800){ref-type="table-fn"}                                                        \<0.001
  IL-10 (ng/L)   57.86±8.09      12.72±2.47[\*](#tfn9-medscimonit-22-2800){ref-type="table-fn"}     20.60±1.89[\*](#tfn9-medscimonit-22-2800){ref-type="table-fn"},[\#](#tfn10-medscimonit-22-2800){ref-type="table-fn"}     16.72±2.11[\*](#tfn9-medscimonit-22-2800){ref-type="table-fn"},[\#](#tfn10-medscimonit-22-2800){ref-type="table-fn"},[&](#tfn11-medscimonit-22-2800){ref-type="table-fn"}   \<0.001
  TNF-α (ng/L)   32.54±9.68      132.18±40.62[\*](#tfn9-medscimonit-22-2800){ref-type="table-fn"}   82.68±15.32[\*](#tfn9-medscimonit-22-2800){ref-type="table-fn"},[\#](#tfn10-medscimonit-22-2800){ref-type="table-fn"}    97.40±16.83[\*](#tfn9-medscimonit-22-2800){ref-type="table-fn"},[\#](#tfn10-medscimonit-22-2800){ref-type="table-fn"}                                                       \<0.001

*P* -- comparisons between control, asthma, AECOPD and ACOS.

Compared with the control group, *P*\<0.05;

Compared with the asthma group, *P*\<0.05;

Compared with the AECOPD group, *P*\<0.05.

AECOPD -- acute exacerbation of chronic obstructive pulmonary disease; ACOS -- asthma-chronic obstructive pulmonary disease overlap syndrome; IL-4 -- interleukin 4; IL-8 -- interleukin 8; IL-10 -- interleukin 10; TNF-α -- tumor necrosis factor alpha.

###### 

Correlations between plasma inflammatory cytokine levels and pulmonary function indexes.

          FEV1     FEV1%pred   FEV1/FVC                      
  ------- -------- ----------- ---------- --------- -------- ---------
  IL-4    0.297    0.003       0.240      0.018     0.390    \<0.001
  IL-8    −0.580   \<0.001     −0.641     \<0.001   −0.455   \<0.001
  IL-10   0.535    \<0.001     0.580      \<0.001   0.477    \<0.001
  TNF-α   −0.494   \<0.001     −0.491     \<0.001   −0.452   \<0.001

FEV1 -- forced expiratory volume in 1 second; FEV1%pred -- FEV1/predicted value ratio; FVC -- forced vital capacity; IL-4 -- interleukin 4; IL-8 -- interleukin 8; IL-10 -- interleukin 10; TNF-α -- tumor necrosis factor alpha.
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